Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment.

ABSTRACT:

Purpose

The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment.

Methods

This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson's correlation coefficient.

Results

Seven patients were enrolled, and 79 blood samples were collected. Among six patients who

SUBMITTER: Sato MT 

PROVIDER: S-EPMC11671551 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature